All In Biotech

Drug Trial Radar · NCT03905694

A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

ILLUMINATE-B: An Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1

Last checked: Nov 20, 2026Latest source record: Feb 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

18

Actual

Start

Apr 22, 2019

Primary completion

Jun 29, 2020

Study completion Jul 26, 2024

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Apr 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of lumasiran in infants and young children with confirmed primary hyperoxaluria type 1 (PH1).

Conditions

  • Primary Hyperoxaluria
  • Primary Hyperoxaluria Type 1 (PH1)

Interventions

  • LumasiranDrug

    Lumasiran will be administered by subcutaneous (SC) injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage Change in Spot Urinary Oxalate:Creatinine Ratio From Baseline to Month 6Time frame: Baseline to Month 6

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Rochester, Minnesota

  • Clinical Trial Site

    Houston, Texas

  • Clinical Trial Site

    Lyon, France

  • Clinical Trial Site

    Paris, France

  • Clinical Trial Site

    Bonn, Germany

  • Clinical Trial Site

    Haifa, Israel

  • Clinical Trial Site

    Jerusalem, Israel

  • Clinical Trial Site

    Nahariya, Israel

  • Clinical Trial Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.